Fatty liver disease
A practical guide for GPs

Background
Non-alcoholic fatty liver disease (NAFLD), encompassing both simple steatosis and non-alcoholic steato-hepatitis (NASH), is the most common cause of liver disease in Australia. Non-alcoholic fatty liver disease needs to be considered in the context of the metabolic syndrome, as cardiovascular disease will account for much of the mortality associated with NAFLD.

Objective
To provide an approach to the identification of NAFLD in general practice, the distinction between simple steatosis and NASH, and the management of these two conditions.

Discussion
Non-alcoholic steato-hepatitis is more common in the presence of diabetes, obesity, older age and increased inflammation, and is more likely to progress to cirrhosis. Cirrhosis may be complicated by hepatocellular carcinoma or liver failure. Hepatocellular carcinoma has also been described in NASH without cirrhosis. Assessment and treatment of features of the metabolic syndrome may reduce associated cardiovascular mortality. Numerous agents have been evaluated, but weight loss remains the only effective treatment for NAFLD.

Keywords
liver diseases; fatty liver

First described in 1980,1 non-alcoholic fatty liver disease (NAFLD) is now the most common cause of liver disease in industrialised countries.2 Non-alcoholic fatty liver disease includes both non-alcoholic steato-hepatitis (NASH), involving lobular inflammation and fibrosis, and simple steatosis (non-NASH). This distinction is important, as simple steatosis is unlikely to lead to liver related complications, whereas NASH may lead to increased fibrosis and cirrhosis, and its complications (Figure 1). The difficulty lies in trying to decide whether raised liver functions tests (LFTs) are due to simple steatosis, NASH without fibrosis, NASH with severe fibrosis or cirrhosis, or another cause of hepatitis altogether.

Epidemiology
The prevalence of NAFLD is estimated to be approximately 30% of adults in developed countries such as Australia and the United States, depending on definition and detection methods.3 However, NAFLD is also becoming increasingly common in Asia (countries previously thought to be at low risk of NAFLD), where a prevalence of up to 15% has been reported in China.4

Natural history
Simple steatosis appears to be a relatively benign condition, although it may progress to NASH over time. Cardiovascular disease is the major cause of death in patients with NAFLD;5 NAFLD alone is associated with a slightly higher overall mortality. However, when NAFLD occurs in the presence of other features of the metabolic syndrome (MetSy), mortality doubles.5 The MetSy is a clustering of cardiovascular risk factors related to reduced insulin sensitivity. Diagnostic criteria for the syndrome include:7
- elevated serum triglycerides (TG)
- lowered serum high-density lipoprotein cholesterol (HDL-C)
- impaired glucose tolerance
- central adiposity
- hypertension.

Although NAFLD is not officially included in the definition of the MetSy, it commonly co-exists with features of this syndrome.

In addition to its association with cardiovascular complications, NAFLD can lead to liver related morbidity and mortality. The risk of developing cirrhosis is higher in the presence of NASH, which is more likely in the presence of the following features:
- type 2 diabetes mellitus (T2DM)
- obesity (body mass index [BMI] >30 kg/m²)
need to be excluded, such as viral hepatitis, autoimmune hepatitis, haemochromatosis, thyroid disease and coeliac disease (Table 1).

**Diagnostic assessment of NAFLD**

A definitive diagnosis of NAFLD depends on three factors:

- evidence of fatty infiltration from either imaging (ultrasound, magnetic resonance imaging [MRI] or histology (liver biopsy)
- exclusion of significant alcohol consumption
- exclusion of other causes of hepatic steatosis (eg. medications, surgery, metabolic disorders).

Confirming hepatic fatty infiltration using ultrasound is important. Specificity is high (95%), but the sensitivity of ultrasound for detecting fatty infiltration is lower (85%). Ultrasound is also useful to look for signs of cirrhosis, such as irregular liver edge, but has a sensitivity of only 43–74% (specificity is slightly higher at 54–89%). Signs of cirrhotic complications are also important, eg. signs of portal hypertension (splenomegaly, increased portal vein size, varices) or other complications such as HCC, portal vein thrombosis, or ascites.

The risk of fibrosis and progressive liver disease in NAFLD increases with severity of insulin resistance. In the absence of simple available clinical measurements of insulin resistance, the number of MetSy features present can be used to estimate risk of insulin resistance. The presence of three or more features of the syndrome, especially if these include central adiposity and T2DM, are predictive of the presence of NASH rather than simple steatosis. In addition, family history plays a role: an individual with a first degree relative with T2DM has a 90% chance of developing T2DM, and therefore NASH. Central adiposity can be assessed using waist circumference measured at the narrowest point mid-way between the lowest rib and the iliac crest at the end of expiration with the patient standing.

Staging liver disease and detecting cirrhosis is the most important aspect of assessing fatty liver disease. However, it is also difficult and error prone. The traditional gold standard in assessing liver disease is liver biopsy. However, biopsy has unfavourable cost, safety, availability, sampling error, inter-observer variability and patient acceptance. Liver biopsy may be considered where cirrhosis is suspected, or where an alternative diagnosis is considered. At this stage, referral to a gastroenterologist is also suggested.

Non-invasive tools for estimating the degree of fibrosis include transient elastography (FibroScan®), acoustic radiation force impulse (ARFI), and non-invasive biomarker algorithms such as NAFLD Fibrosis Score, FibroTest and Hepascore. However, their use in clinical practice is still being evaluated.

**Management of NAFLD**

**Cardiovascular risk factors and lifestyle modification**

The cornerstone to managing NAFLD is achieving weight control and reduction in cardiovascular risk factors such as smoking, diabetes, hypertension and dyslipidaemia. This may include referral to a dietician,
Fatty liver disease – a practical guide for GPs

NAFLD should be considered when abnormal LFTs are found, particularly in the presence of features of the MetSy.

Weight reduction via caloric restriction and regular exercise are important, and no medications can currently be recommended as specific therapy.

General practitioners are vital in identifying patients at risk of NAFLD, and encouraging initiation and maintenance of appropriate lifestyle changes.

### Table 1. What to consider and how to exclude differential diagnoses

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excess alcohol consumption</td>
<td>Careful, corroborative history</td>
</tr>
<tr>
<td>Chronic hepatitis B</td>
<td>HBsAg, anti-HBs, anti-HBc</td>
</tr>
<tr>
<td>Chronic hepatitis C</td>
<td>Hepatitis C antibody</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>Anti-nuclear antibody (ANA) Anti-smooth-muscle antibody (ASMA) Anti-mitochondrial antibody (AMA)</td>
</tr>
<tr>
<td>Haemochromatosis</td>
<td>Iron studies</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>Thyroid function tests</td>
</tr>
<tr>
<td>Coeliac disease</td>
<td>Coeliac antibodies (usually deamidated antigliadin antibody, tissue transglutaminase, total IgA level)</td>
</tr>
<tr>
<td>Medications</td>
<td>History of amiodarone, anticonvulsants, methotrexate, tamoxifen, synthetic oestrogens, corticosteroids, HIV therapy, perhexiline</td>
</tr>
</tbody>
</table>

### Novel treatments

Various therapeutic agents have shown some promise in the management of NAFLD. However, weight loss remains the only therapy with proven benefit and safety.

### What follow up should be performed?

A pragmatic approach to the investigation and management of NAFLD is presented in Figure 2. Normalisation of LFTs associated with mild weight loss may be an encouraging sign that the disease activity is driven by NAFLD. However, it is important to stage the disease initially (with ultrasound and histology if appropriate). The presence of normal LFTs does not exclude underlying cirrhosis, nor does a ‘non-cirrhotic’ ultrasound. Monitoring full blood examination (FBE), LFTs, International Normalised Ratio (INR), blood pressure and lipid profile every 6 months is a reasonable approach.

### When to refer for specialist management

Referral for specialist management should be undertaken whenever there is a suspicion of severe fibrosis or cirrhosis, whether at initial assessment or at any time during monitoring.

### Key points

- Non-alcoholic fatty liver disease is increasingly common, and will have a significant impact on morbidity and mortality on a growing number of Australians.

---

```
Table 1. What to consider and how to exclude differential diagnoses

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excess alcohol consumption</td>
<td>Careful, corroborative history</td>
</tr>
<tr>
<td>Chronic hepatitis B</td>
<td>HBsAg, anti-HBs, anti-HBc</td>
</tr>
<tr>
<td>Chronic hepatitis C</td>
<td>Hepatitis C antibody</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>Anti-nuclear antibody (ANA) Anti-smooth-muscle antibody (ASMA) Anti-mitochondrial antibody (AMA)</td>
</tr>
<tr>
<td>Haemochromatosis</td>
<td>Iron studies</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>Thyroid function tests</td>
</tr>
<tr>
<td>Coeliac disease</td>
<td>Coeliac antibodies (usually deamidated antigliadin antibody, tissue transglutaminase, total IgA level)</td>
</tr>
<tr>
<td>Medications</td>
<td>History of amiodarone, anticonvulsants, methotrexate, tamoxifen, synthetic oestrogens, corticosteroids, HIV therapy, perhexiline</td>
</tr>
</tbody>
</table>
```

---

```
Figure 2. Algorithm for management of suspected NAFLD

Likely NAFLD after exclusion of other common liver diseases

NAFLD not excluded, but consider other causes +/- specialist referral

Evidence of NAFLD on liver ultrasound?

Evidence of cirrhosis or portal hypertension?

Central adiposity, obesity, diabetes, metabolic syndrome

6 month lifestyle adjustment (diet/exercise)

Improvement in LFTs and liver ultrasound?

Specialist referral and consideration of liver biopsy

Reinforce positive changes
Monitor other risk factors

- NAFLD should be considered when abnormal LFTs are found, particularly in the presence of features of the MetSy.
- Weight reduction via caloric restriction and regular exercise are important, and no medications can currently be recommended as specific therapy.
- General practitioners are vital in identifying patients at risk of NAFLD, and encouraging initiation and maintenance of appropriate lifestyle changes.
```
Further reading


Authors

David Iser MBBS(Hons), BMedSc, FRACP, PhD, is a gastroenterologist, Department of Gastroenterology, St Vincent’s Hospital, Melbourne and Infectious Diseases Unit, The Alfred Hospital, Melbourne, Victoria. david.iser@svhm.org.au
Marno Ryan MBBS(Hons), FRACP, MD, is a gastroenterologist, Department of Gastroenterology, St Vincent’s Hospital, Melbourne, Victoria.

Competing interests: None.

Provenance and peer review: Commissioned; externally peer reviewed.

References


correspondence afp@racgp.org.au